摘要
本研究首次报告氨磷汀(AMF)治疗不同年龄特发性血小板减少性紫癜(ITP)患者的近期疗效及其副作用。应用AMF治疗17例ITP患者。治疗方案为AMF0.4g静脉滴注,连续5天为1周期,每两周期之间停药2天,连续4周期为1个疗程。结果表明:17例患者经1疗程治疗后血小板水平达到正常,且在停止治疗2月以后血小板仍保持在正常水平,不需要继续予以激素、丙种球蛋白等其他治疗,不需要输血,生存质量改善。AMF没有明显的毒副作用,但有些胃肠道反应,能够有效克服,患者均可耐受。结论:氨磷汀首创性地应用于不同年龄特发性血小板减少性紫癜患者的治疗并取得较好疗效,且副作用少,因此氨磷汀对于ITP患者治疗具有良好的应用前景,是一种很有潜力的药物,尤其对于难治性高龄患者更是一种安全、有效的药物,有关氨磷汀的长期临床疗效和作用机理有待于进一步研究。
The objective of this study was to explore the effect of amifostine （AMF） in treating patients with idiopathic thrombocytopenic purpura （ITP） and its adverse effects. 17 ITP patients（aged from 13 to 92, mean 65 years ） were treated with AMF and their therapeutic regimen was following： 0.4 g AMF was dissolved in 100 ml physiological saline, the intravenous drop was performed at day and lasted 5 days per week, with interval 2 days, 4 weeks were considered as a course of treatment. The results showed that the normal counts of platelets were observed in 17 ITP patients after 1 course of treatment, and remaind unchanged for 2 months following stop of therapy. In that time, no any drugs such as hormonal preparation, γ-globulin, blood transfusion and so on were given in all treated patients, the main adverse effect of AMF was discomform in digective system that all patients could endure, Therefore, the patient＇s life quality was obviouoly improved. It is concluded that the AMF has been initially and successfully used to treat ITP patients with positive response, and may be considered as a safe-effective drug for treating old patients with ITP, but the longterm effect and pharmacological mechamism of this drug needs further evaluation.
出处
《中国实验血液学杂志》
CAS
CSCD
2008年第1期192-196,共5页
Journal of Experimental Hematology
